Nanotech Investing Ventyx Biosciences Announces Positive Topline Results from Phase 2 Study of VTX3232 in Participants with Obesity and Cardiovascular Risk Factors 22 October
Nanotech Investing Ventyx Biosciences to Participate in Three Upcoming Investor Conferences 27 August
